

CK5/14 + p63 + CK7/18

Prediluted Multiplex Antibody
901-360VP-101923

BIOCARE
M E D I C A L

Available Product Formats				
Format	Catalog Number	Description	Dilution	Diluent
UltraLine – For BenchMark	VP 360DSK G	6.0 mL	Ready-to-use	N/A

Intended Use:

For *in vitro* Diagnostic Use

CK5/14 + p63 + CK7/18 is a blend of mouse monoclonal and rabbit monoclonal antibodies that is intended for professional laboratory use after the initial diagnosis of tumor has been made by conventional histopathology using nonimmunologic histochemical stains, in the qualitative identification of keratins CK5, CK7, CK14, and CK18, and p63 proteins by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist as an aid in making any other clinical determinations.

Summary and Explanation:

CK5/14 + p63 + CK7/18 is comprised of mouse monoclonal anti-CK5, anti-CK14, and anti-p63 antibodies and rabbit monoclonal anti-CK7 and anti-CK18 antibodies. CK5 and CK14 are high molecular weight keratins expressed in the cytoplasm of basal cells and myoepithelium of breast tissue.¹⁵⁻¹⁸ p63 is a transcription factor present in the nuclei of myoepithelial cells.^{16,18} In contrast, CK7 and CK18 are low molecular weight cytokeratins primarily expressed in luminal cells of the breast.^{15-17.}

CK5, CK14, p63, CK7 and CK18 have routinely been used as IHC markers to complement morphological evaluation in the assessment of breast lesions, due to the differential expression of the luminal vs. basal and myoepithelial markers.¹⁵⁻¹⁹ Cases of usual ductal hyperplasia (UDH) have been associated with expression of the basal cell markers, intermixed with cells expressing the keratins of luminal cells.^{15,16,20-24} Most cases of atypical ductal hyperplasia (ADH) and low grade ductal carcinoma in situ (LG-DCIS) were negative for the basal markers and exhibited an immunophenotype indicative of luminal cells.^{15,19-22} Additionally, the basal phenotype has been shown to be characterized by luminal expression of the basal and myoepithelial markers, using a cocktail of CK5, CK14 and p63.²⁵⁻²⁷

IHC, using CK5, CK14, p63, CK7 and CK18 antibodies, evaluated in combination with hematoxylin and eosin (H&E), has been shown to significantly increase inter-observer agreement amongst pathologists, compared to H&E alone.²⁸

Principle of Procedure:

This antibody cocktail product may be used as the primary antibody in immunohistochemistry testing of formalin-fixed, paraffin-embedded tissue sections. In general, immunohistochemical (IHC) staining techniques allow for the visualization of antigens via the sequential application of a specific antibody cocktail to the antigen (primary antibody), a secondary antibody cocktail containing anti-rabbit and anti-mouse enzyme complexes to the primary antibody and the chromogenic substrates with interposed washing steps. The enzymatic activation of the chromogens results in a visible reaction product at the antigen sites. The specimen may then be counterstained, and cover slipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.

Materials and Methods:

Reagents Provided:

CK5/14 + p63 + CK7/18 (VP360DSK) is provided as follows:

1. VP401G CK5 + CK14 + p63

Antibody	anti-CK5	anti-CK14	anti-p63
Host Source	Mouse monoclonal	Mouse monoclonal	Mouse monoclonal
Species Reactivity:	Human. Other species not tested.		
Clone	XM26	LL002	4A4
Isotype	IgG1/kappa	IgG3	IgG2a/kappa
Protein Concentration:	Contact Biocare's Technical Support for specific Ig concentration		
Specificity	CK5	CK14	p63
Cellular Localization	Cytoplasmic	Cytoplasmic	Nuclear
Staining	Brown (DAB)	Brown (DAB)	Brown (DAB)

2. VP402G CK7 + CK18

Antibody	anti-CK7	anti-CK18
Host Source	Rabbit monoclonal	Rabbit monoclonal
Species Reactivity:	Human. Other species not tested.	
Clone	BC1	EP30*
Isotype	IgG	IgG
Protein Concentration:	Contact Biocare's Technical Support for specific Ig concentration	
Specificity	CK7	CK18
Cellular Localization	Cytoplasmic	Cytoplasmic
Staining	Red	Red

*Previously known as E431-1

Method:

CK5: Tissue culture supernatant mouse monoclonal.

CK14 and p63: Affinity purified mouse monoclonal.

CK7 and CK18: Affinity purified rabbit monoclonal.

Reconstitution, Mixing, Dilution, Titration:

Prediluted antibody reagent is optimally diluted for use with the below automated staining platform. Further dilution may result in loss of antigen staining. The user must validate any such change. Differences in tissue processing and technical procedures in the user's laboratory may produce significant variability in results necessitating regular performance of in-house controls (see Quality Control section).

Known Applications:

Immunohistochemistry (formalin-fixed paraffin-embedded tissues)



60 Berry Drive
Pacheco, CA 94553
USA



TP v2 (02/10/2023)

Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080



Westervoortsedijk 60
6827 AT Arnhem
The Netherlands

CK5/14 + p63 + CK7/18

Prediluted Multiplex Antibody
901-360VP-101923

BIOCARE
M E D I C A L

Supplied As:

VP401 CK5 + CK14 + p63

Buffered saline solution, pH 5.9 – 6.0, containing a protein carrier and less than 0.1% sodium azide preservative. See Safety Data Sheet for additional details.

VP402 CK7 + CK18

Buffered saline solution, pH 5.9 – 6.0, containing a protein carrier and less than 0.1% sodium azide preservative. See Safety Data Sheet for additional details.

Materials and Reagents Needed but Not Provided:

Microscope slides positively charged.
Positive and negative tissue controls
Desert Chamber (or similar Drying oven)
Xylene or xylene substitute
Ethanol or reagent alcohol
Decloaking Chamber (Pressure cooker)
Deionized or distilled water
Wash buffer
Pretreatment reagents
Peroxidase block
Protein block (optional)
Detection probe and polymer
Negative control reagents
Chromogens
Hematoxylin (counterstain)
Bluing reagent
Mounting medium
Coverglass
Light Microscope (40-400X magnification)
Ventana Benchmark ULTRA

Configurations of the antibody product are available for use on the instruments indicated in the table above.

Storage and Stability:

Store at 2°C to 8°C. The product is stable to the expiration date printed on the vial label, when stored under these conditions. Do not use after expiration date. Storage under any condition other than those specified must be verified. Diluted reagents should be used promptly; store any remaining reagent at 2°C to 8°C. The stability of user diluted reagent has not been established by Biocare.

Positive and negative controls should be run simultaneously with all patient specimens. If unexpected staining is observed which cannot be explained by variations in laboratory procedures and a problem with the antibody is suspected, contact Biocare's Technical Support at 1-800-542-2002 or via the technical support information provided on biocare.net.

Specimen Preparation:

Tissues fixed in formalin are suitable for use prior to paraffin embedding. Osseous tissues should be decalcified prior to tissue processing to facilitate tissue cutting and prevent damage to microtome blades.^{1,2}

Properly fixed and embedded tissues expressing the specified antigen target should be stored in a cool place. The Clinical Laboratory Improvement Act (CLIA) of 1988 requires in 42 CFR §493.1259(b) that "The laboratory must retain stained slides at least ten years from the date of examination and retain specimen blocks at least two years from the date of examination."³

Treatment of Tissues Prior to Staining:

Perform Heat Induced Epitope Retrieval (HIER) per recommended protocol below. The routine use of HIER prior to IHC has been shown to minimize inconsistency and standardize staining.^{4,5}

Warning and Precautions:

1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN₃) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976)⁶
2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come into contact with sensitive areas, wash with copious amounts of water.⁷
3. Microbial contamination of reagents may result in an increase in nonspecific staining.
4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.
5. Do not use reagent after the expiration date printed on the vial.
6. Prediluted antibody reagent is optimally diluted for use. Further dilution may result in loss of antigen staining.
7. Dilution of concentrated antibody reagent must be validated before use. Any diluent used that is not specifically recommended also must be validated for compatibility and stability.
8. Dispose of all used reagents and any other contaminated disposable materials following procedures for infectious or potentially infectious waste. It is the responsibility of each laboratory to handle solid and liquid waste according to their nature and degree of hazardousness and to treat and dispose of it (or have them treated and disposed of) in accordance with any applicable regulations.
9. Follow local disposal regulations for your location along with recommendations in the Safety Data Sheet to determine the safe disposal of this product
10. The SDS is available upon request and is located at <http://biocare.net>.

Instructions for Use:

Recommended Staining Protocols for CK5/14 + p63 + CK7/18:

Ventana BenchMark ULTRA:

VP360DSK is intended for use with the BenchMark ULTRA. Refer to the User Manual for specific instructions for use. Recommended protocol parameters are as follows:	
Template/Detection:	IHC DS uDAB-uRed Template
Pretreatment Protocol:	CC1 Standard
Primary Antibody (VP401):	32 minutes, 37°C
Ultrawash:	N/A
Primary Antibody (VP402):	32 minutes, 37°C
Detection:	ultraView DAB and AP Detections

Quality Control:

Refer to CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2) CLSI Wayne, PA USA (www.clsi.org). 2011⁸

Positive Tissue Control: Breast carcinoma

External Positive control materials should be fresh specimens fixed, processed, and embedded as soon as possible in the same manner as the patient sample(s). Positive tissue controls are indicative of correctly prepared tissues and proper staining techniques. One positive external tissue control for each set of test conditions should be included in each staining run.

The tissues used for the external positive control materials should be selected from patient specimens with well-characterized low levels of the positive target activity that gives weak positive staining. The low level of positivity for external positive controls is designed to ensure detection of subtle changes

CK5/14 + p63 + CK7/18

Prediluted Multiplex Antibody
901-360VP-101923

BIOCARE
M E D I C A L

in the primary antibody sensitivity from instability or problems with the IHC methodology. Commercially available tissue control slides or specimens processed differently from the patient sample(s) validate reagent performance only and do not verify tissue preparation.

Known positive tissue controls should only be utilized for monitoring the correct performance of processed tissues and test reagents, rather than as an aid in formulating a specific diagnosis of patient samples. If the positive tissue controls fail to demonstrate positive staining, results with the test specimens should be considered invalid.

Negative Tissue Control:

Use a negative tissue control (known to be CK5/14 + p63 + CK7/18 negative) fixed, processed, and embedded in a manner identical to the patient sample(s) with each staining run to verify the specificity of the IHC primary antibody for demonstration of the target antigen, and to provide an indication of specific background staining (false positive staining). Also, the variety of different cell types present in most tissue sections can be used by the laboratorian as internal negative control sites to verify the IHC's performance specifications. The types and sources of specimens that may be used for negative tissue controls are listed in the Performance Characteristics section.

If specific staining (false positive staining) occurs in the negative tissue control, results with the patient specimens should be considered invalid.

Nonspecific Negative Reagent Control:

Use a nonspecific negative reagent control in place of the primary antibody with a section of each patient specimen to evaluate nonspecific staining and allow better interpretation of specific staining at the antigen site. Ideally, a negative reagent control contains a CK5 IgG1, CK14 IgG3, p63 IgG2a, CK7 IgG, and CK18 IgG antibody produced from purified sera or tissue culture supernatant in the same way as the primary antibodies but exhibits no specific reactivity with human tissues in the same matrix/solution as the Biocare antibody. Dilute a negative control antibody to the same immunoglobulin or protein concentration as the diluted primary antibody using the identical diluent. If fetal calf serum is retained in the neat antibody after processing, fetal calf serum at a protein concentration equivalent to the diluted primary antibody in the same diluent is also suitable for use. (Refer to reagent provided). Diluent alone may be used as a less desirable alternative to the previously described negative reagent controls. The incubation period for the negative reagent control should correspond to that of the primary antibody.

When panels of several antibodies are used on serial sections, the negatively staining areas of one slide may serve as a negative/nonspecific binding background control for other antibodies. To differentiate endogenous enzyme activity or nonspecific binding of enzymes from specific immunoreactivity, additional patient tissues may be stained exclusively with substrate-chromogen or enzyme complexes (PAP, avidin-biotin, streptavidin) and substrate-chromogen, respectively.

Assay Verification:

Prior to initial use of an antibody or staining system in a diagnostic procedure, the user should verify the antibody's specificity by testing it on a series of in-house tissues with known immunohistochemical performance characteristics representing known positive and negative tissues. Refer to the quality control procedures previously outlined in this section of the product insert and to the quality control recommendations of the CAP Certification Program⁹ for Immunohistochemistry and/or the NCCLS IHC guideline¹⁰). These quality control procedures should be repeated for each new antibody lot, or whenever there is a change in assay parameters. Tissues listed in the Performance Characteristics Section are suitable for assay verification.

Troubleshooting:

Follow the antibody specific protocol recommendations according to the data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.

Interpretation of Staining:

Positive Tissue Control:

The positive tissue control stained with indicated antibody should be examined first to ascertain that all reagents are functioning properly. The appropriate staining of target cells (as indicated above) is indicative of positive reactivity. If the positive tissue controls fail to demonstrate positive staining, any results with the test specimens should be considered invalid.

The color of the reaction product may vary depending on substrate chromogens used. Refer to substrate package inserts for expected color reactions. Further, metachromasia may be observed in variations of the method of staining.¹¹

When a counterstain is used, depending on the incubation length and potency of the counterstain used, counterstaining will result in a coloration of the cell nuclei. Excessive or incomplete counterstaining may compromise proper interpretation of results. Refer to protocol(s) for recommended counterstain.

Negative Tissue Control:

The negative tissue control should be examined after the positive tissue control to verify the specificity of the labeling of the target antigen by the primary antibody. The absence of specific staining in the negative tissue control confirms the lack of antibody cross reactivity to cells/cellular components. If specific staining (false positive staining) occurs in the negative external tissue control, results with the patient specimen should be considered invalid.

Nonspecific staining, if present, usually has a diffuse appearance. Sporadic staining of connective tissue may also be observed in sections from excessively formalin-fixed tissues. Use intact cells for interpretation of staining results. Necrotic or degenerated cells often stain nonspecifically.

Patient Tissue:

Examine patient specimens stained with indicated antibody last. Positive staining intensity should be assessed within the context of any nonspecific background staining of the negative reagent control. As with any immunohistochemical test, a negative result means that the antigen was not detected, not that the antigen was absent in the cells/tissue assayed. If necessary, use a panel of antibodies to identify false-negative reactions.

Refer to Summary and Explanation, Limitations, and Performance Characteristics for specific information regarding indicated antibody immunoreactivity.

Limitations:

General Limitations:

1. For *in vitro* diagnostic Use
2. This product is for professional use only: Immunohistochemistry is a multistep diagnostic process that consists of specialized training in the selection of the appropriate reagents; tissue selection, fixation, and processing; preparation of the IHC slide; and interpretation of the staining results.
3. Tissue staining is dependent on the handling and processing of the tissue prior to staining. Improper fixation, freezing, thawing, washing, drying, heating, sectioning or contamination with other tissues or fluids may produce artifacts, antibody trapping, or false negative results. Inconsistent results may be due to variations in fixation and embedding methods, or to inherent irregularities within the tissue.¹²



60 Berry Drive
Pacheco, CA 94553
USA



TP v2 (02/10/2023)

Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080



Westervoortsedijk 60
6827 AT Arnhem
The Netherlands

CK5/14 + p63 + CK7/18

Prediluted Multiplex Antibody
901-360VP-101923

BIOCARE
M E D I C A L

- Excessive or incomplete counterstaining may compromise proper interpretation of results.
- The clinical interpretation of any positive or negative staining should be evaluated within the context of clinical presentation, morphology, and other histopathological criteria. The clinical interpretation of any positive or negative staining should be complemented by morphological studies using proper positive and negative internal and external controls as well as other diagnostic tests. It is the responsibility of a qualified pathologist who is familiar with the proper use of IHC antibodies, reagents, and methods to interpret all the steps used to prepare and interpret the final IHC preparation.
- The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions.
- This product is not intended for use in flow cytometry. Performance characteristics have not been determined for flow cytometry.
- Tissues from persons infected with hepatitis B virus and containing hepatitis B surface antigen (HBsAg) may exhibit nonspecific staining with horseradish peroxidase.¹³
- Reagents may demonstrate unexpected reactions in previously untested tissues. The possibility of unexpected reactions even in tested tissue groups cannot be completely eliminated due to biological variability of antigen expression in neoplasms, or other pathological tissues.¹⁴ Contact Biocare's Technical Support at 1-800-542-2002, or via the technical support information provided on biocare.net, with documented unexpected reaction(s).
- Normal/nonimmune sera from the same animal source as secondary antisera used in blocking steps may cause false-negative or false-positive results due to autoantibodies or natural antibodies.
- False-positive results may be seen due to non-immunological binding of proteins or substrate reaction products. They may also be caused by pseudo peroxidase activity (erythrocytes), endogenous peroxidase activity (cytochrome C), or endogenous biotin (e.g., liver, breast, brain, kidney) depending on the type of immunostain used.¹²

Product Specific Limitations:

No additional product specific limitations noted.

Troubleshooting:

- No staining of any slides – Check to determine appropriate positive control tissue, antibody, and detection products have been used.
- Weak staining of all slides – Check to determine appropriate positive control tissue, antibody, and detection products have been used.
- Excessive background of all slides – There may be high levels of endogenous biotin (if using biotin-based detection products), endogenous HRP activity converting chromogen to colored end product (use peroxidase block), or excess non-specific protein interaction (use a protein block, such as serum- or casein-based blocking solution).
- Tissue sections wash off slides during incubation – Check slides to ensure they are positively charged.
- Specific staining too dark – Check protocol to determine of proper antibody titer was applied to slide, as well as proper incubation times for all reagents. Additionally, ensure the protocol has enough washing steps to remove excess reagents after incubation steps are completed.

References:

- Kiernan JA. Histological and Histochemical Methods: Theory and Practice. New York: Pergamon Press 1981.
- Sheehan DC and Hrapchak BB. Theory and Practice of Histotechnology. St. Louis: C.V. Mosby Co. 1980.
- Clinical Laboratory Improvement Amendments of 1988: Final Rule, 57 FR 7163, February 28, 1992.
- Shi S-R, Cote RJ, Taylor CR. J Histotechnol. 1999 Sep;22(3):177-92.
- Taylor CR, et al. Biotech Histochem. 1996 Jan;71(5):263-70.
- Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts."
- Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.
- CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2) CLSI Wayne, PA USA (www.clsi.org). 2011
- College of American Pathologists (CAP) Certification Program for Immunohistochemistry. Northfield IL. <http://www.cap.org> (800) 323-4040.
- O'Leary TJ, Edmonds P, Floyd AD, Mesa-Tejada R, Robinowitz M, Takes PA, Taylor CR. Quality assurance for immunocytochemistry; Proposed guideline. MM4-P. National Committee for Clinical Laboratory Standards (NCCLS). Wayne, PA. 1997;1-46.
- Koretz K, Lemain ET, Brandt I, and Moller P. Metachromasia of 3-amino-9-ethylcarbazole (AEC) and its prevention in Immunoperoxidase techniques. Histochemistry 1987; 86:471-478.
- Nadji M, Morales AR. Immunoperoxidase, part I: the techniques and its pitfalls. Lab Med 1983; 14:767.
- Omata M, Liew CT, Ashcavai M, Peters RL. Nonimmunologic binding of horseradish peroxidase to hepatitis B surface antigen: a possible source of error in immunohistochemistry. Am J Clin Path 1980; 73:626.
- Herman GE and Elfont EA. The taming of immunohistochemistry: the new era of quality control. Biotech & Histochem 1991; 66:194.
- Hicks DG. Immunohistochemistry in the Diagnostic Evaluation of Breast Lesions. Appl Immunohistochem Mol Morph. 2011; 19:501-5.
- Moriya T, et al. New trends of immunohistochemistry for making differential diagnosis of breast lesions. Med Mol Morphol. 2006; 39:8-13.
- Yeh IT, Mies C. Application of Immunohistochemistry to Breast Lesions. Arch Pathol Lab Med. 2008; 132:349-57.
- Lerwill MF. Current Practical Applications of Diagnostic Immunohistochemistry in Breast Pathology. Am J Surg Pathol. 2004; 28:1076-91.
- Moriya T, et al. Usefulness of immunohistochemistry for differential diagnosis between benign and malignant breast lesions. Breast Cancer. 2009; 16:173-8.
- Otterbach F, et al. Cytokeratin 5/6 immunohistochemistry assists in differential diagnosis of atypical proliferations of the breast. Histopathology. 2000; 37:232-40.
- Lacroix-Triki M, et al. Value of cytokeatin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody. Virchows Arch. 2003; 442:548-54.
- Boecker W, et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol. 2002; 198:458-67.
- Koo JS, et al. Comparison of Immunohistochemical Staining in Breast Papillary Neoplasm of Cytokeratin 5/6 and p63 in core Needle Biopsies and Surgical Excisions. Appl Immunohistochem Mol Morph. 2012; 20:108-15.
- Ichihara S, et al. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. Path Int. 2007; 57:126-32.
- Livasy CA, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006; 19:264-71.



60 Berry Drive
Pacheco, CA 94553
USA



TP v2 (02/10/2023)

Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080

EC REP EMERGO EUROPE

Westervoortsedijk 60

6827 AT Arnhem

The Netherlands

CK5/14 + p63 + CK7/18

Prediluted Multiplex Antibody
901-360VP-101923

BIOCARE
M E D I C A L

26. Laakso M, et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. *Mod Pathol.* 2005; 18:1321-8.
27. Bhargava R, et al. CK5 is More Sensitive than CK5/6 in Identifying the "Basallike" Phenotype of Breast Carcinoma. *Am J Clin Pathol.* 2008; 130:724-30.
28. Jain RK, et al. Atypical ductal hyperplasia: interobserver and intraobserver variability. *Mod Pathol.* 2011; 24:917-23.

Ultraline antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare antibodies by Ventana Medical Systems, Inc or Roche. Biocare, Ventana and Roche are not affiliated, associated, or related in any way. Ventana®, BenchMark®, ultraView and OptiView are trademarks of Roche.

Anti-CK18: Produced using Abcam's RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.